iBio and GE Healthcare (GE) form new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines (IBIO) 1.29 : The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio's plant-based vaccine manufacturing platform, iBioLaunch, with GE Healthcare's capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio's research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.
fast track to broad market use.. and royalty revenue imo
RGEN $3.78, Sheff could you share your current thoughts on RGEN please. Do you think this gets straightened out and getting any momo again in the next couple months? I glance over it now and then and think what promise she had, still think she does, just requires a lil patience obviously. Feels like this $3.70's area is close to a bottom, if not the bottom.